Seminars in Oncology
Volume 31, Issue 6 , Pages 802-808 , December 2004

Strategies to overcome accelerated repopulation and hypoxia—what have we learned from clinical trials?

  • June Corry

      Affiliations

    • Head and Neck Radiation Oncology Unit, Division of Radiation Oncology, University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia.
    • ,
  • Danny Rischin

      Affiliations

    • D.R. has acted as a consultant for Sanofi-Synthelabo.
    • Head and Neck Medical Oncology Unit, Division of Haematology and Medical Oncology, University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia.
    • Corresponding Author InformationAddress reprint requests to Danny Rischin, MBBS (Hons), FRACP, Division of Haematology and Medical Oncology, Locked Bag No 1, A’Beckett St, Melbourne, Australia 8006

References 

  1. Peters LJ , Fletcher GH . Causes of failure of radiotherapy in head and neck cancer . Radiother Oncol . 1983;1:53–63
  2. Hermens AF , Barendsen GW . Changes of cell proliferation characteristics in a rat rhabdomyosarcoma before and after x-irradiation . Eur J Cancer . 1969;5:173–189
  3. Withers HR , Taylor JM , Maciejewski B . The hazard of accelerated tumor clonogen repopulation during radiotherapy . Acta Oncol . 1988;27:131–146
  4. Horiot JC , Bontemps P , van den Bogaert W , et al.   Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers (Results of the EORTC 22851 randomized trial) . Radiother Oncol . 1997;44:111–121
  5. Dische S , Saunders M , Barrett A , et al.   A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer . Radiother Oncol . 1997;44:123–136
  6. Jackson SM , Weir LM , Hay JH , et al.   A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer . Radiother Oncol . 1997;43:39–46
  7. Poulsen MG , Denham JW , Peters LJ , et al.   A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck (A Trans-Tasman Radiation Oncology Group Study) . Radiother Oncol . 2000;60:113–122
  8. Skladowski K , Maciejewski B , Golen M , et al.   Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer—Report on 3-year tumour control and normal tissue toxicity . Radiother Oncol . 2000;55:101–110
  9. Bourhis JLM , Torochaux J , et al.   Very accelerated versus conventional radiotherapy in HNSCC (Results of the GORTEC 94–02 randomized trial) . Int J Radiat Oncol Biol Phys . 2000;48(suppl):S111; (abstr)
  10. Overgaard J , Hansen HS , Specht L , et al.   Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck (DAHANCA 6 and 7 randomised controlled trial) . Lancet . 2003;362:933–940
  11. Fu KK , Pajak TF , Trotti A , et al.   A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas (First report of RTOG 9003) . Int J Radiat Oncol Biol Phys . 2000;48:7–16
  12. Hansen O , Overgaard J , Hansen HS , et al.   Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma (Dependency on tumor differentiation) . Radiother Oncol . 1997;43:47–51
  13. Schmidt-Ullrich RK , Mikkelsen RB , Dent P , et al.   Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation . Oncogene . 1997;15:1191–1197
  14. Eriksen J , Steiniche T , Alsner J , et al.   The prognostic significance of EGFr is related to tumor cell differentiation and the fractionation of radiotherapy in squamous cell carcinoma of the head and neck . Proceedings of the 2nd ESTRO Workshop in Biology in Radiation Oncology . Netherlands: Berg en Dal/Nijmegen; 2003; June 1–3
  15. Calais G , Alfonsi M , Bardet E , et al.   Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma . J Natl Cancer Inst . 1999;91:2081–2086
  16. Brizel DM , Albers ME , Fisher SR , et al.   Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer . N Engl J Med . 1998;338:1798–1804
  17. Jeremic B , Shibamoto Y , Stanisavljevic B , et al.   Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck (A prospective randomized trial) . Radiother Oncol . 1997;43:29–37
  18. Wendt TG , Grabenbauer GG , Rodel CM , et al.   Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer (A randomized multicenter study) . J Clin Oncol . 1998;16:1318–1324
  19. Adelstein DJ , Li Y , Adams GL , et al.   An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer . J Clin Oncol . 2003;21:92–98
  20. Staar S , Rudat V , Stuetzer H , et al.   Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy—Results of a multicentric randomized German trial in advanced head-and-neck cancer . Int J Radiat Oncol Biol Phys . 2001;50:1161–1171
  21. Overgaard J , Horsman MR . Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers . Semin Radiat Oncol . 1996;6:10–21
  22. Nordsmark M , Overgaard M , Overgaard J . Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck . Radiother Oncol . 1996;41:31–39
  23. Brizel DM , Sibley GS , Prosnitz LR , et al.   Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck . Int J Radiat Oncol Biol Phys . 1997;38:285–289
  24. Stadler P , Becker A , Feldmann HJ , et al.   Influence of the hypoxic subvolume on the survival of patients with head and neck cancer . Int J Radiat Oncol Biol Phys . 1999;44:749–754
  25. Rudat V , Stadler P , Becker A , et al.   Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer . Strahlenther Onkol . 2001;177:462–468
  26. Vanselow B , Eble MJ , Rudat V , et al.   Oxygenation of advanced head and neck cancer (Prognostic marker for the response to primary radiochemotherapy) . Otolaryngol Head Neck Surg . 2000;122:856–862
  27. Gatenby RA , Kessler HB , Rosenblum JS , et al.   Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy . Int J Radiat Oncol Biol Phys . 1988;14:831–838
  28. Olive PL , Banath JP , Aquino-Parsons C . Measuring hypoxia in solid tumours—Is there a gold standard? . Acta Oncol . 2001;40:917–923
  29. Nordsmark M , Loncaster J , Aquino-Parsons C , et al.   Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas . Radiother Oncol . 2003;67:35–44
  30. Nozue M , Lee I , Yuan F , et al.   Interlaboratory variation in oxygen tension measurement by Eppendorf “histograph” and comparison with hypoxic marker . J Surg Oncol . 1997;66:30–38
  31. Kaanders JH , Wijffels KI , Marres HA , et al.   Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer . Cancer Res . 2002;62:7066–7074
  32. Evans SM , Hahn S , Pook DR , et al.   Detection of hypoxia in human squamous cell carcinoma by EF5 binding . Cancer Res . 2000;60:2018–2024
  33. Rasey JS , Koh WJ , Evans ML , et al.   Quantifying regional hypoxia in human tumors with positron emission tomography of [18F] fluoromisonidazole (A pretherapy study of 37 patients) . Int J Radiat Oncol Biol Phys . 1996;36:417–428
  34. Rischin D , Peters L , Hicks R , et al.   Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer . J Clin Oncol . 2001;19:535–542
  35. Dolbier WR , Li AR , Koch CJ , et al.   [18F]-EF5, a marker for PET detection of hypoxia (Synthesis of precursor and a new fluorination procedure) . Appl Radiat Isot . 2001;54:73–80
  36. Sorger D , Patt M , Kumar P , et al.   [18F] fluoroazomycinarabinofuranoside (18FAZA) and [18F] fluoromisonidazole (18FMISO) (A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors) . Nucl Med Biol . 2003;30:317–326
  37. Takahashi N , Fujibayashi Y , Yonekura Y , et al.   Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer . Ann Nucl Med . 2000;14:323–328
  38. Rischin D , Peters L , Smith J , et al.   Preliminary results of TROG 98.02—A randomised phase II study of 5-fluorouracil, cisplatin and radiation versus tirapazamine, cisplatin and radiation for advanced squamous cell carcinoma of the head and neck . Proc Am Soc Clin Oncol . 2003;22:495; (abstr 1991)
  39. Haffty BG , Hurley R , Peters LJ . Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck (results of a randomized clinical trial) . Cancer J Sci Am . 1999;5:341–347
  40. Henk JM , Kunkler PB , Smith CW . Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial . Lancet . 1977;2:101–103
  41. Overgaard J . Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors . Oncol Res . 1994;6:509–518
  42. Overgaard J , Hansen HS , Overgaard M , et al.   A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5–85 . Radiother Oncol . 1998;46:135–146
  43. Bernier J , Denekamp J , Rojas A , et al.   ARCON: Accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC) . Radiother Oncol . 2000;55:111–119
  44. Kaanders JH , Pop LA , Marres HA , et al.   ARCON (experience in 215 patients with advanced head-and-neck cancer) . Int J Radiat Oncol Biol Phys . 2002;52:769–778
  45. Brown JM . SR 4233 (tirapazamine) (A new anticancer drug exploiting hypoxia in solid tumours) . Br J Cancer . 1993;67:1163–1170
  46. Brown JM , Lemmon MJ . Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors . Cancer Res . 1990;50:7745–7749
  47. Dorie MJ , Brown JM . Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin . Cancer Res . 1993;53:4633–4636
  48. Koch CJ . Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin . Cancer Res . 1993;53:3992–3997
  49. Hliniak A , Gwiazdowska B , Szutkowski Z , et al.   A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer (Influence of a 1 week shortening overall time) . Radiother Oncol . 2002;62:1–10

PII: S0093-7754(04)00402-6

doi: 10.1053/j.seminoncol.2004.09.005

Seminars in Oncology
Volume 31, Issue 6 , Pages 802-808 , December 2004

Article Tools

* Image Usage & Resolution